ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versu…

ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated, commercial-stage immunotherapy company, today announced that based ...
Stocktwits on MSN

ImmunityBio says phase 2 bladder cancer trial has ‘statistical power’ – Anktiva-BCG advances toward filing

ImmunityBio (IBRX) said on Thursday that its QUILT-2.005 clinical trial evaluating Anktiva plus Bacillus Calmette-Guérin (BCG ...

ImmunityBio lead bladder cancer drug trial clears power check

ImmunityBio Inc. IBRX shares are down during Thursday’s premarket session. Year to date, the stock has jumped over 300%. The ...
CU Boulder News & Events

M1. Hypothesis Testing, Effect Sizes, and Statistical Power

Basic concepts in hypothesis testing, including effect sizes, type I and type II errors, calculation of statistical power, non-centrality parameter, and applications of these concepts to twin studies.